HER2 Climb 05

from OncoPharm · host John Bossaer

Tucatinib gets an expanded FDA approval in the 1st-line treatment of HER2(+) metastatic breast cancer based on the results of HER2-Climb05. Pirtobrutinib also gets FDA approved for initial treatment of CLL/SLL (without 17p deletion). Australia makes a bold decision regarding Nivo/Ipi and Pembrolisumab: https://doi.org/10.1200/JCO-26-01340 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Episode metadata supplied by the publisher feed · Published Oct 8, 2026

Embed this episode

Attribution link and audio player

Ready to play

HER2 Climb 05

0:00 13:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 13 minutes long.

When was this OncoPharm episode published?

This episode was published on October 8, 2026.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!